scispace - formally typeset
O

Onno W. Akkerman

Researcher at University Medical Center Groningen

Publications -  150
Citations -  2916

Onno W. Akkerman is an academic researcher from University Medical Center Groningen. The author has contributed to research in topics: Tuberculosis & Medicine. The author has an hindex of 23, co-authored 118 publications receiving 1898 citations. Previous affiliations of Onno W. Akkerman include University of Groningen.

Papers
More filters
Journal ArticleDOI

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

Nafees Ahmad, +107 more
- 08 Sep 2018 - 
TL;DR: Treatment outcomes were significantly better with use of linezolid, later generation fluoroquinolones, bedaquiline, clofazimine, and carbapenems for treatment of multidrug-resistant tuberculosis, and the need for trials to ascertain the optimal combination and duration of these drugs is emphasised.
Journal ArticleDOI

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study

Sergey Borisov, +64 more
TL;DR: Bedaquiline-containing regimens achieved high conversion and success rates under different nonexperimental conditions, and is safe and effective in treating MDR- and XDR-TB patients.
Journal ArticleDOI

Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020.

Giovanni Battista Migliori, +57 more
TL;DR: Data showed that attendance at tuberculosis centers was lower during the first 4 months of the pandemic in 2020 than for the same period in 2019.
Journal ArticleDOI

MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network.

Giovanni Battista Migliori, +104 more
TL;DR: The review comprehensively describes the latest information on contact tracing and LTBI management in MDR-TB contacts, while providing guidance on post-treatment functional evaluation and rehabilitation of TB sequelae, infection control and other public health priorities.
Journal ArticleDOI

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report

Sergey Borisov, +90 more
TL;DR: This global project (658 patients from 26 countries) demonstrates aDSM is feasible and serious adverse events of recommended drugs are reasonably low (overall 57 out of 504, 11.3%), but implementation needs scaling up to support patient-centred care.